US3621LQ1099 - GTHX - A2DR0J (XNAS)
G1 THERAPEUTICSCS INC Aktie
7,14 USD
Aktuelle Kurse von G1 THERAPEUTICSCS INC
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
GTHX
|
USD
|
18.09.2024 01:44
|
7,14 USD
| 7,15 USD | -0,14 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | 0,14 % | 0,42 % | 178,91 % | 122,43 % | 379,19 % | -79,92 % |
Firmenprofil zu G1 THERAPEUTICSCS INC Aktie
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Investierte Fonds
Folgende Fonds haben in G1 THERAPEUTICSCS INC investiert:
Fonds | Vol. in Mio 20,33 | Anteil (%) 0,05 % |
Unternehmensdaten zur G1 THERAPEUTICSCS INC Aktie
Name G1 THERAPEUTICSCS INC
Firma G1 Therapeutics, Inc.
Symbol GTHX
Website https://www.g1therapeutics.com
Heimatbörse
NASDAQ
WKN A2DR0J
ISIN US3621LQ1099
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. John E. Bailey Jr.
Marktkapitalisierung 376 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,1 T
Adresse 700 Park Offices Drive, 27709 Research Triangle Park
IPO Datum 2017-05-17
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | G1H.F |
NASDAQ | GTHX |
Weitere Aktien
Investoren die G1 THERAPEUTICSCS INC halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024